Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberWO2006028645 B1
Publication typeApplication
Application numberPCT/US2005/028564
Publication dateNov 6, 2008
Filing dateAug 12, 2005
Priority dateSep 2, 2004
Also published asUS20060052304, WO2006028645A2, WO2006028645A3
Publication numberPCT/2005/28564, PCT/US/2005/028564, PCT/US/2005/28564, PCT/US/5/028564, PCT/US/5/28564, PCT/US2005/028564, PCT/US2005/28564, PCT/US2005028564, PCT/US200528564, PCT/US5/028564, PCT/US5/28564, PCT/US5028564, PCT/US528564, WO 2006/028645 B1, WO 2006028645 B1, WO 2006028645B1, WO-B1-2006028645, WO2006/028645B1, WO2006028645 B1, WO2006028645B1
InventorsDennis R Stewart
ApplicantBas Medical Inc, Dennis R Stewart
Export CitationBiBTeX, EndNote, RefMan
External Links: Patentscope, Espacenet
Method for remodeling bone and related sutures
WO 2006028645 B1
Abstract
The invention relates to the discovery that relaxin receptors exist in bone and related sutures. As such, bone can be remodeled, repaired, removed or grown. Particularly, the invention pertains to a method for modifying a target bone by administering a relaxin compound which binds to relaxin receptors and by monitoring a change in the target bone. The invention further encompasses methods of modifying the height of a human subject.
Amended Claims  (OCR text may contain errors)
AMENDED CLAIMS received by the International Bureau on 18 July 2008 (18.07.08)WHAT IS CLAIMED IS:
1. A method for modifying a target bone in a mammalian subject, said method comprising: (i) administering a relaxin compound to said subject wherein said compound binds to a relaxin receptor in the target bone; and
(ii) monitoring a change in the target bone, wherein said change results in a modified target bone selected from the group consisting of remodeled bone, repaired bone, bone grown in size and bone grown in length.
2. The method of claim 1 , wherein said modifying of the target bone is selected from the group consisting of growing, remodeling and repairing.
3. The method of claim 1, wherein said change is selected from the group consisting of bone growth, bone strength, bone movement, bone location, bone removal, bone deposition and bone fracture repair.
4. The method of claim 1, wherein said repaired bone is selected from the group consisting of a bone fracture, a bone malformation and a bone tumor.
5. The method of claim 1 , wherein said target bone is any bone that comprises osteoblasts and osteoclasts.
6. The method of claim 1, wherein said relaxin compound is selected from the group consisting of Hl relaxin, H2 relaxin, H3 relaxin, relaxin-like factor (RLF) and combinations thereof.
7. The method of claim 6, wherein said Hl relaxin binds to a relaxin receptor selected from the group consisting of LGR7 and LGR8.
8. The method of claim 6, wherein said H2 relaxin binds to a relaxin receptor selected from the group consisting of LGR7 and LGR8.
28
9. The method of claim 6, wherein said H3 relaxin binds to a relaxin receptor selected from the group consisting of GPCR135 and GPCR142.
10. The method of claim 1, wherein said relaxin compound is a relaxin analog that functions as a receptor agonist.
11. The method of claim 10, wherein said receptor agonist is a compound that binds to said relaxin receptor in the target bone and activates said relaxin receptor.
12. The method of claim 1, wherein said relaxin compound is a relaxin analog that functions as a receptor antagonist.
13. The method of claim 12, wherein said receptor antagonist is a compound that binds to said relaxin receptor in the target bone and blocks said relaxin receptor.
14. The method of claim 1, wherein said relaxin receptor is found in bone tissue selected from the group consisting of osteoblasts, osteoclasts, osteocytes, odontoblasts and chondrocytes.
15. The method of claim 1 , wherein said relaxin receptor is found in bone marrow tissue selected from the group consisting of mature myeloid elements of erythrocytes and mature myeloid elements of leukocytes.
16. The method of claim 1, wherein said relaxin receptor is found in bone marrow tissue of immature myeloid elements that are composed of hemocytoblasts, erythroblasts, myelocytes and megakaryocytes.
17. The method of claim 1, wherein said relaxin receptor is found in a sutural ligament.
18. The method of claim 1, wherein said mammalian subject is selected from the group consisting of human, dog, cat, rat, mouse and horse.
19. The method of claim 1, wherein said relaxin receptor is selected from the group consisting of LGR7, LGR8, GPCR135 and GPCR142.
20. A method for modifying height in a human subject, said method comprising:
(i) administering a relaxin compound to said human subject wherein said compound binds to a relaxin receptor in a target bone; and
(ii) monitoring said subject for a change in said height, wherein said target bone is selected from the group consisting of long bones of the limbs, skeletal bones and vertebral bones.
21. The method of claim 20, wherein said height is increased between about 0.2 to about 30 cm.
22. The method of claim 20, wherein said human subject is between about 8 and about 18 years of age.
23. The method of claim 20, wherein said human subject is a patient suffering from a condition selected from the group consisting of delayed growth, arthritis, Paget's disease, avascular necrosis, fibrous dysplasia, osteogenesis imperfecta (OI), primary hyperparathyroidism and growth hormone deficiency (GHD), growth hormone insensitivity syndrome (GHIS), and osteoporosis.
24. A method for repairing a target bone in a mammalian subject, said method comprising: (i) administering a relaxin compound to said subject wherein said compound binds to a relaxin receptor in the target bone; and
(ii) monitoring a change in the target bone, wherein said change results in a repaired target bone selected from the group consisting of a bone fracture, a bone malformation and a bone tumor.
Classifications
International ClassificationA61K38/00
Cooperative ClassificationA61K38/2221, A61K38/1709
European ClassificationA61K38/17A2, A61K38/22C
Legal Events
DateCodeEventDescription
Mar 16, 2006AKDesignated states
Kind code of ref document: A2
Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
Mar 16, 2006ALDesignated countries for regional patents
Kind code of ref document: A2
Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
Aug 30, 2006121Ep: the epo has been informed by wipo that ep was designated in this application
Mar 3, 2007NENPNon-entry into the national phase in:
Ref country code: DE
Sep 26, 2007122Ep: pct app. not ent. europ. phase